Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teun van Gelder

Showing results (71-80 of 324) with videos related to

Pageof 33
Sort By:
European Journal of Clinical Pharmacology|May 6, 2009
Unintended consequences of reducing QT-alert overload in a computerized physician order entry systemHeleen van der Sijs, Ravi Kowlesar, Jos Aarts, et al.
Clinical Pharmacokinetics|November 20, 2013
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantationDennis A Hesselink, Rachida Bouamar, Laure Elens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Reply to N. Singh et alRoelof Wouter Frederik van Leeuwen, Teun van Gelder, Joachim G Aerts, et al.
British Journal of Clinical Pharmacology|October 28, 2023
Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?Suwasin Udomkarnjananun, Thanee Eiamsitrakoon, Brenda C M de Winter, et al.
Currents in Pharmacy Teaching & Learning|September 19, 2022
Clinical reasoning by pharmacists: A scoping reviewJosephine F Mertens, Ellen S Koster, Vera H M Deneer, et al.
Therapeutic Drug Monitoring|October 16, 2015
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive DrugsNicolas Picard, Stein Bergan, Pierre Marquet, et al.
The Lancet. Oncology|October 5, 2014
Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' replyRoelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, et al.
Therapeutic Drug Monitoring|January 19, 2006
Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of viewReinier M van Hest, Ron A Mathot, Arnold G Vulto, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Brenda C M de Winter, Ron A A Mathôt, Reinier M van Hest, et al.
The Lancet. Oncology|July 4, 2014
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspectiveRoelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, et al.
Pageof 33

Showing results (71-80 of 324) with videos related to

Sort By:
Pageof 33
European Journal of Clinical Pharmacology|May 6, 2009
Unintended consequences of reducing QT-alert overload in a computerized physician order entry systemHeleen van der Sijs, Ravi Kowlesar, Jos Aarts, et al.
Clinical Pharmacokinetics|November 20, 2013
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantationDennis A Hesselink, Rachida Bouamar, Laure Elens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Reply to N. Singh et alRoelof Wouter Frederik van Leeuwen, Teun van Gelder, Joachim G Aerts, et al.
British Journal of Clinical Pharmacology|October 28, 2023
Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?Suwasin Udomkarnjananun, Thanee Eiamsitrakoon, Brenda C M de Winter, et al.
Currents in Pharmacy Teaching & Learning|September 19, 2022
Clinical reasoning by pharmacists: A scoping reviewJosephine F Mertens, Ellen S Koster, Vera H M Deneer, et al.
Therapeutic Drug Monitoring|October 16, 2015
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive DrugsNicolas Picard, Stein Bergan, Pierre Marquet, et al.
The Lancet. Oncology|October 5, 2014
Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' replyRoelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, et al.
Therapeutic Drug Monitoring|January 19, 2006
Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of viewReinier M van Hest, Ron A Mathot, Arnold G Vulto, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Brenda C M de Winter, Ron A A Mathôt, Reinier M van Hest, et al.
The Lancet. Oncology|July 4, 2014
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspectiveRoelof W F van Leeuwen, Teun van Gelder, Ron H J Mathijssen, et al.
Pageof 33